Trial Profile
A Phase II Trial of Capecitabine in Combination With the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Tipifarnib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Feb 2010 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.